ERBB2阳性早期乳腺癌患者皮下 vs 静脉曲妥珠单抗:HannaH 3期随机临床试验最终分析
HannaH试验6年随访最终分析纳入596例ERBB2阳性早期乳腺癌患者,比较皮下曲妥珠单抗600 mg与静脉曲妥珠单抗(负荷8 mg/kg、维持6 mg/kg)的疗效与安全性;两组6年无事件生存率和总生存率相似,不良事件、心脏事件及严重不良事件发生率相当,支持皮下曲妥珠单抗作为替代给药途径。
要点
- 皮下与静脉曲妥珠单抗6年无事件生存率均为65%(HR 0.98,95%CI 0.74-1.29)。
- 两组6年总生存率均为84%(HR 0.94,95%CI 0.61-1.45)。
- 达到病理学完全缓解者无事件生存期更长、6年总生存率更高。
核心结论
- HannaH试验最终分析进一步证实皮下与静脉曲妥珠单抗的疗效和安全性相当,并支持皮下曲妥珠单抗作为ERBB2阳性早期乳腺癌患者的替代给药途径。
研究设计与样本
- 开放标签、前瞻性、多中心、国际、新辅助-辅助、随机、3期非劣效性临床试验,主要终点为病理学完全缓解和第8周期给药前血清谷浓度。
- 共纳入596例ERBB2阳性早期乳腺癌患者,入组时间为2009年10月19日至2010年12月1日。
- 皮下组294例女性(平均[SD]年龄50.3[11.1]岁),静脉组297例女性(平均[SD]年龄49.5[10.8]岁),分别纳入意向治疗人群。
主要发现
- 6年无事件生存率两组均为65%(HR 0.98,95%CI 0.74-1.29)。
- 6年总生存率两组均为84%(HR 0.94,95%CI 0.61-1.45)。
- 达到总病理学完全缓解的患者较有残留病变者无事件生存期更长、6年总生存率更高。
- 皮下组 vs 静脉组不良事件发生率:290/297(97.6%) vs 282/298(94.6%)。
- 皮下组 vs 静脉组3级及以上不良事件:158/297(53.2%) vs 160/298(53.7%);心脏事件:44/297(14.8%) vs 42/298(14.1%);严重不良事件:65/297(21.9%) vs 45/298(15.1%)。
关键数值与推荐
- 皮下曲妥珠单抗固定剂量600 mg,每3周一次;静脉曲妥珠单抗负荷剂量8 mg/kg、维持剂量6 mg/kg,每3周一次。
- 新辅助阶段接受8周期化疗(多西他赛75 mg/m2×4周期,继以氟尿嘧啶500 mg/m2、表柔比星75 mg/m2、环磷酰胺500 mg/m2×4周期)联合曲妥珠单抗。
- 术后辅助阶段根据初始随机接受额外10周期皮下或静脉曲妥珠单抗,以完成1年抗ERBB2治疗。
临床怎么用
- 作者认为皮下曲妥珠单抗可作为ERBB2阳性早期乳腺癌患者的替代给药途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)-positive early breast cancer after 6 years' follow-up in the HannaH (Enhanced Treatment With Neoadjuvant Herceptin) trial. DESIGN, SETTING, AND PARTICIPANTS: Open-label, prospective, multicenter, international, neoadjuvant-adjuvant, randomized, phase 3 noninferiority clinical trial (primary end points: pathologic complete response and serum trough concentration predose cycle 8) conducted for 596 patients with ERBB2-positive early breast cancer enrolled from October 19, 2009, to December 1, 2010. INTERVENTIONS: Eligible patients received 8 cycles of chemotherapy (4 cycles of docetaxel, 75 mg/m2, followed by 4 cycles of fluorouracil, 500 mg/m2, epirubicin, 75 mg/m2, and cyclophosphamide, 500 mg/m2) with either fixed-dose subcutaneous trastuzumab, 600 mg, or intravenous trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) every 3 weeks in the neoadjuvant setting. Patients received an additional 10 cycles of subcutaneous trastuzumab or intravenous trastuzumab (according to their initial randomization) after surgery in the adjuvant setting to complete 1 year of anti-ERBB2 therapy. MAIN OUTCOMES AND MEASURES: Event-free and overall survival rates were calculated using the Kaplan-Meier method. Hazard ratios were estimated by Cox proportional hazards regression. Adverse events and serious adverse events were graded per standard criteria. RESULTS: In total, 294 women (mean [SD] age, 50.3 [11.1] years) treated with subcutaneous trastuzumab and 297 women (mean [SD] age, 49.5 [10.8] years) treated with intravenous trastuzumab were included in respective intention-to-treat populations. Six-year event-free survival rates (65% in both study groups; hazard ratio, 0.98; 95% CI, 0.74-1.29) and overall survival rates (84% in both study groups; hazard ratio, 0.94; 95% CI, 0.61-1.45) were similar between the subcutaneous and intravenous trastuzumab groups. Patients achieving a total pathologic complete response had longer event-free survival and higher 6-year overall survival rates than those with residual disease. Incidence of adverse events (290 of 297 [97.6%] vs 282 of 298 [94.6%]), grade 3 or higher adverse events (158 of 297 [53.2%] vs 160 of 298 [53.7%]), cardiac events (44 of 297 [14.8%] vs 42 of 298 [14.1%]), and serious adverse events (65 of 297 [21.9%] vs 45 of 298 [15.1%]) was comparable between the subcutaneous and intravenous trastuzumab treatment groups. CONCLUSIONS AND RELEVANCE: This final analysis of the HannaH trial further confirms the comparable efficacy and safety of subcutaneous and intravenous trastuzumab and highlights the suitability of subcutaneous trastuzumab as an alternative route of administration for patients with ERBB2-positive early breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00950300.
引用
- Jackisch C, Stroyakovskiy D, Pivot X, et al. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30998824. doi:10.1001/jamaoncol.2019.0339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。